NAD+ IV Drip

Based on available evidence, clinical applications for NAD+ IV drip are limited and largely investigational. The current evidence base is sparse, with most research focusing on oral NAD+ precursors rather than intravenous administration.

Documented Applications

Anti-aging and Wellness
A 2026 systematic review examined NAD+ supplementation for anti-aging purposes, though this primarily covered oral supplementation rather than IV administration. The review provides limited insight into the clinical efficacy of intravenous NAD+ specifically.

Tolerability Assessment
One retrospective pilot study (2026) compared the tolerability of intravenous NAD+ versus nicotinamide riboside in a real-world clinical setting. However, specific tolerability outcomes and patient populations studied are not detailed in the available abstracts.

Investigational Applications

Current clinical trials suggest potential applications under investigation:

Hematopoietic Recovery
One Phase 1 trial (NCT06558253) is examining "Coenzyme I for Injection" (likely referring to NAD+) for promoting blood cell recovery after umbilical cord blood transplantation, though this study is still recruiting participants.

Vascular Aging
A planned clinical trial (NCT07328100) aims to evaluate NAD+ injection for vascular aging, but this study has not yet begun recruiting.

Evidence Limitations

The clinical evidence for NAD+ IV drip remains extremely limited. Most available studies focus on related compounds like nicotinamide riboside or nicotinamide mononucleotide administered orally, rather than intravenous NAD+ directly. The few studies mentioning intravenous administration provide insufficient detail about clinical outcomes, optimal dosing, or patient selection criteria.

Disclaimer: This information is for educational purposes only and should not replace professional medical advice. Consult with a healthcare provider before considering any NAD+ IV therapy, as clinical evidence for safety and efficacy remains limited.